- Home
- SW vs INSM Comparison
SW vs INSM Comparison
Compare SW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SW
- INSM
- Stock Information
- Founded
- SW 1934
- INSM 1988
- Country
- SW Ireland
- INSM United States
- Employees
- SW N/A
- INSM N/A
- Industry
- SW
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- SW
- INSM Health Care
- Exchange
- SW Nasdaq
- INSM Nasdaq
- Market Cap
- SW 23.9B
- INSM 26.0B
- IPO Year
- SW N/A
- INSM 2000
- Fundamental
- Price
- SW $46.91
- INSM $145.10
- Analyst Decision
- SW Strong Buy
- INSM Strong Buy
- Analyst Count
- SW 8
- INSM 19
- Target Price
- SW $57.25
- INSM $142.38
- AVG Volume (30 Days)
- SW 4.1M
- INSM 3.0M
- Earning Date
- SW 10-29-2025
- INSM 10-30-2025
- Dividend Yield
- SW 3.67%
- INSM N/A
- EPS Growth
- SW N/A
- INSM N/A
- EPS
- SW 0.68
- INSM N/A
- Revenue
- SW $30,806,000,000.00
- INSM $398,105,000.00
- Revenue This Year
- SW $53.37
- INSM $32.47
- Revenue Next Year
- SW $3.23
- INSM $126.03
- P/E Ratio
- SW $69.19
- INSM N/A
- Revenue Growth
- SW 162.45
- INSM 21.15
- 52 Week Low
- SW $37.01
- INSM $60.40
- 52 Week High
- SW $56.99
- INSM $146.84
- Technical
- Relative Strength Index (RSI)
- SW 57.41
- INSM 79.86
- Support Level
- SW $45.42
- INSM $128.02
- Resistance Level
- SW $47.80
- INSM $146.84
- Average True Range (ATR)
- SW 1.16
- INSM 3.66
- MACD
- SW 0.30
- INSM 0.71
- Stochastic Oscillator
- SW 84.81
- INSM 91.65
About SW Smurfit WestRock plc Ordinary Shares
Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.